Literature DB >> 11126401

Severe hypertriglyceridaemia in Type II diabetes: involvement of apoC-III Sst-I polymorphism, LPL mutations and apo E3 deficiency.

C Marçais1, S Bernard, M Merlin, M Ulhmann, B Mestre, L Rochet-Mingret, A Revol, F Berthezene, P Moulin.   

Abstract

AIMS/HYPOTHESIS: Hypertriglyceridaemia is common in Type II (non-insulin-dependent) diabetes mellitus. Only subgroups of patient however have type V hyperlipidaemia. To investigate the coordination between genetic factors in the modulation of hypertriglyceridaemia in Type II diabetes, we studied three major modifier loci: apoC-III (both Sst-I and insulin-responsive element polymorphisms), apolipoprotein E genotypes and lipoprotein-lipase mutations.
METHODS: We studied apoCIII gene polymorphisms, apolipoprotein E genotypes and lipoprotein-lipase gene mutations in 176 patients with Type II (non-insulin-dependent) diabetes mellitus, either normolipaemic (group N, n = 116), mildly hypertriglyceridaemic (group T, n = 28) or with a history of severe hypertriglyceridaemia (triglyceride > 15 g/l) (group H, n = 32).
RESULTS: Mild hypertriglyceridaemia in Type II diabetes did not associate with any gene variants in this study. Severe hypertriglyceridaemia was, however, associated with the presence of the apoC-III S2 allele (50% of the patients in group H compared with 15.5 % in group N, p < 0.0001). Additionally this particular phenotype was associated with a low prevalence of the apo E3 allele (35.9% in group H vs 18.1 % in group N, p < 0.005) and a statistically significant over-representation of the E2E4 genotypes. Inactivating lipoprotein-lipase mutations were found in four patients (three heterozygotes, one homozygote), none was found in group N or T. Thus 68.7 % of group H patients (22/32) (vs 21.4 % in group T, p < 0.0005) were carriers of either S2 allele, lipoprotein-lipase mutants or E2E4 genotype with most lipoprotein-lipase mutants or E2E4 genotypes or both in the non-carriers for the S2 allele (6/7). CONCLUSION/
INTERPRETATION: Our results strongly support the hypothesis that severe hyperlipaemia in Type II diabetes crucially depends on genetic factors which impair the clearance of triglyceride-rich lipoproteins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11126401     DOI: 10.1007/s001250051537

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  8 in total

1.  An APOA5 3' UTR variant associated with plasma triglycerides triggers APOA5 downregulation by creating a functional miR-485-5p binding site.

Authors:  Cyrielle Caussy; Sybil Charrière; Christophe Marçais; Mathilde Di Filippo; Agnès Sassolas; Mireille Delay; Vanessa Euthine; Audrey Jalabert; Etienne Lefai; Sophie Rome; Philippe Moulin
Journal:  Am J Hum Genet       Date:  2014-01-02       Impact factor: 11.025

2.  Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment.

Authors:  Christophe Marçais; Bruno Verges; Sybil Charrière; Valérie Pruneta; Micheline Merlin; Stéphane Billon; Laurence Perrot; Jocelyne Drai; Agnès Sassolas; Len A Pennacchio; Jamila Fruchart-Najib; Jean-Charles Fruchart; Vincent Durlach; Philippe Moulin
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 3.  Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.

Authors:  Alison B Kohan
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-04       Impact factor: 3.243

4.  Association of lipoprotein lipase (LPL) single nucleotide polymorphisms with type 2 diabetes mellitus.

Authors:  Yoon Shin Cho; Min Jin Go; Hye Ree Han; Seung Hun Cha; Hung Tae Kim; Haesook Min; Hyoung Doo Shin; Chan Park; Bok Ghee Han; Nam Han Cho; Chol Shin; Kuchan Kimm; Bermseok Oh
Journal:  Exp Mol Med       Date:  2008-10-31       Impact factor: 8.718

5.  Post-heparin LPL activity measurement using VLDL as a substrate: a new robust method for routine assessment of plasma triglyceride lipolysis defects.

Authors:  Mathilde Di Filippo; Christophe Marçais; Sybil Charrière; Oriane Marmontel; Martine Broyer; Mireille Delay; Micheline Merlin; Axel Nollace; René Valéro; Michel Lagarde; Valérie Pruneta-Deloche; Philippe Moulin; Agnès Sassolas
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

6.  High fat diet modifies the association of lipoprotein lipase gene polymorphism with high density lipoprotein cholesterol in an Asian Indian population.

Authors:  K A Ayyappa; I Shatwan; D Bodhini; L R Bramwell; K Ramya; V Sudha; R M Anjana; J A Lovegrove; V Mohan; V Radha; K S Vimaleswaran
Journal:  Nutr Metab (Lond)       Date:  2017-01-19       Impact factor: 4.169

7.  Lipolysis, and not hepatic lipogenesis, is the primary modulator of triglyceride levels in streptozotocin-induced diabetic mice.

Authors:  Florian Willecke; Diego Scerbo; Prabhakara Nagareddy; Joseph C Obunike; Tessa J Barrett; Mariane L Abdillahi; Chad M Trent; Lesley A Huggins; Edward A Fisher; Konstantinos Drosatos; Ira J Goldberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-11-13       Impact factor: 8.311

Review 8.  Role of the Gut in Diabetic Dyslipidemia.

Authors:  Priska Stahel; Changting Xiao; Avital Nahmias; Gary F Lewis
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-13       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.